Alzheimer's Research Update 7-17-13
Science Daily January 9 reports on positive results from an experimental treatment which appears to bring about a reversal of Alzheimer's symptoms. The study was reported in the Journal of Neuroinflammation. Marked improvement was achieved withing moments of the administration of a therapeutic molecule. If this promising development proves to be effective it will of major importance to millions who are afflicted by this previously virtually undreatable condition.
The experimental treatment focuses on a substance that regulates the brain's transmission of neural impulses in the brain. When this soluble protein or cytokine TNF is present in excessive concentration it interferes with the brain's neural functioning. The experimental breakthrough was achieved by the injection of an anti-TNF therapeutic called etanercept (trade name Enbrel). Enbrel or etanercept is currently available and approved for treatment of other conditions. Here's a link to the Science Daily report.
COMMENT From NYT: "New diagnostic tests are leading to a moral dilemma. Since there is no
treatment for Alzheimer’s, is it a good thing to tell people, years
earlier, that they have this progressive degenerative brain disease or
have a good chance of getting it?" 12-17-10
7-17-13NYTimes--"Looking for Early Symptoms of Dementia?--Ask the Paitent"
- Looking for Early Signs of Dementia? Ask the Patient - NYTimes.com
Doctors are starting to pay more attention to patients who say they are experiencing cognitive problems but do not yet show a measurable decline.
5-7-13NYTimes "Promising Alzheimer's Treatment Fails, Baxter Says"
- Baxter, a Drug Maker, Says Its New Alzheimer’s Treatment Has Failed - NYTimes.com
Baxter International said that the immunoglobulin therapy did not significantly arrest the decline in either cognition or daily functioning when compared with a placebo.
4-29-13BloombergBusinessWeek "The Killer Cost of Alzheimer's"
- Alzheimer's: The Costliest Killer - Businessweek
"If nothing is done, Alzheimer's will become the 'financial sinkhole of the 21st century,' says gerontologist Ken Dichtwald, chief executive officer of Age Wave, a consulting firm."
4-16-13NYTimes--For the Elderly Where Diseases Overlap
- For the Elderly, Diseases That Overlap - Interactive Feature - NYTimes.com
Most residents in assisted-living centers suffer from multiple ailments--e.g., alzheimers, high blood pressure, heart disease.
4-3-13NYTimes--Dementia Care Costs Are Soaring
- Dementia Care Costs Are Soaring, Study Finds - NYTimes.com
The number of people with dementia and the cost of caring for them will more than double in 25 years, rising at a rate uncommon for a chronic disease, new academic research found.
3-18-13NYTimes EDITORIAL "Drugs for Early Stage Alzheimer's"
- Drugs for Early-Stage Alzheimer’s - NYTimes.com
A proposal to ease testing requirements is seductive but raises concerns about safety.
Wall Street Journal--Meet Dr. Sid Gilman, Alzheimer's Researcher at University of Michigan Medical School Who Pleaded Guilty to Insider Trading Violations Recen
- Meet the Doctor in the Middle of the Newest Insider-Trading Case - Law Blog - WSJ
An alleged $276 million insider-trading scheme involving a former portfolio manager at a unit of SAC Capital Advisors LP has also ensnared a professor at the University of Michigan Medical School, Dr. Sid Gilman.
2-12-13NYTimes--"Straining to Hear and Fend off Dementia"
- Straining to Hear and Fend Off Dementia - NYTimes.com
There is no clear explanation why, but compared with individuals with normal hearing, those with hearing loss have an increased risk of developing dementia. Read more...
11-9-12WallStreetJournal "An Outcast Among Peers Gains Traction on Alzheimer's Cure" by Jeanne Whalen
- An Outcast Among Peers Gains Traction on Alzheimer's Cure - WSJ.com
Dr. Claude Wischik has embraced an idea that, if he is right, could ultimately spin Alzheimer's research on its heels—and raise new hopes for the roughly 36 million people world-wide afflicted with Alzheimer's or dementia.
7-18-12NYTimes--Small Trial Hints Drug Can Slow Alzheimer's
- Trial Hints Baxter’s Gammagard Can Slow Alzheimer’s - NYTimes.com
Some Alzheimer’s patients who used the therapy, already approved for immune disorders, showed no worsening of symptoms for three years.
7-17-12NYTimes Science--Cognitive Decline Linked to Changes in Walking Gait
- Signs of Cognitive Decline and Alzheimer’s Are Seen in Gait - NYTimes.com
Five studies presented this month provide striking evidence that when a person’s walk gets slower or becomes more variable or less controlled, his cognitive function is also suffering.
7-16-12WallStreetJournal--For Alzheimer's a Fork in the Road
- For Alzheimer's, a Fork in the Road - WSJ.com
"This is a watershed year" for Alzheimer's research, said Norman Relkin, a neurologist and neuroscientist at the Weill Cornell Medical College in New York, who isn't involved with any of these trials.
6-10-12NYTimesMagazine: "How Do You Live Knowing You Might Have an Alzheimer’s Gene?" by Gina Kolata
- An Alzheimer’s Gene - One Family’s Saga - NYTimes.com
One family with a genetic mutation is helping scientists find a cure.
2-1-12NYTimes "Faulty Protein is Like a Virus in Alzheimers" Gina Kolata
- Faulty Protein is Like a Virus in Alzheimers, Studies Find - NYTimes.com
Discovery in studies of mice solves a mystery surrounding the disease’s grim march and has immediate implications for developing treatments, researchers said. Instead of viruses or bacteria, what is being spread is a distorted protein known as tau.
9-13-11NYTimes "A Squirt of Insulin May Delay Alzheimers"
- Squirts of Insulin May Help Those With Early Alzheimers - NYTimes.com
An intriguing study suggests that aerosolized insulin may help people who are in the early stages of Alzheimers.
8-23-11NYTimes--Tennessee Basketball Coach Reveals Dementia Diagnosis
- Tennessees Summitt Reveals Dementia Diagnosis - NYTimes.com
Pat Summitt, the Tennessee womens basketball coach, said she hoped to manage the disease and planned to coach in the coming season.
4-3-11NYTimes--Gina Kolata--"Genetic Component in Alzheimers Study"
- Alzheimers Studies Show Genetic Links - NYTimes.com
The two largest studies of Alzheimers disease led to the discovery of five genes that provide intriguing new clues to why it strikes and how it progresses.
12-18-10NYTimes---Moral Dilemma Over Early Alzheimer's Test
- Early Alzheimer's Detection--Poses a Moral Dilemma
The new diagnostic tests are leading to a moral dilemma. Since there is no treatment for Alzheimers, is it a good thing to tell people, years earlier, that they have this progressive degenerative brain disease or have a good chance of getting it?
9-1-10NYTimes--Protein Discovery May Set New Target for Alzheimer's Drugs
- Protein Discovery May Result in New Alzheimer's Drugs
The finding, to be published Thursday in the journal Nature, reveals a new potential drug target that, according to the prevailing hypothesis of the genesis of Alzheimers, could slow or halt the devastating effects of this now untreatable disease.
- Doubt on Tactic in Alzheimer's Battle
The failure of a promising Alzheimers drug in clinical trials highlights the gap between diagnosis where real progress has recently been made and treatment of the disease...It was that the drug actually made them worse, the company said.
8-16-10NYTimes--Eli Lily Stops Tests of Alzheimer's Drug
- Alzheim'er's drug made patients worse so Eli Lily stopped the tests.
In yet another setback in efforts to treat Alzheimers disease, Eli Lilly & Company announced on Tuesday that it had halted development of an experimental treatment after the compound actually made patients worse in two late-stage clinical trials.
8-11-10NYTimes--Rare Sharing of Data Leads to Progress on Alzheimer's
- Alzheimer's Data Sharing Brings Progress
Scientists and executives from the NIH, the FDA, the drug and medical-imaging industries, universities and nonprofits joined in a project that had no precedent: a collaborative effort to find the biological markers of the progression of Alzheimer's.
8-10-10National Public Radio--Sorting When Early Memory Loss Signals Big Thrreat
- Early Memory Loss
1 million people a year begin a mental slide called mild cognitive impairment, or MCI, with forgetfulness that's somewhere between healthy aging and Alzheimer's. Now this gray zone is evolving, with growing study of techniques to help predict...
NYTimes 8-10-10Spinal fluid test predicts Alzheimer's
- Spinal Fluid Test Predicts Alzheimer's
Researchers report that a spinal fluid test can be 100 percent accurate in identifying patients with significant memory loss who are on their way to developing Alzheimers disease.
Hope on the Horizon for Alzheimer's Treatment
Enbrel is currently FDA approved for rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthrytis, alkylosing spondilitis and chronic plaque psoriasis. The drug is quite expensive and can have serious side effects. More linked below.